相关临床试验
3
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1906
进行中（未招募）
3
100.0%
暂无批准数据
- Recent randomized controlled trials present conflicting evidence on left bundle branch area pacing (LBBAP) versus traditional biventricular pacing for cardiac resynchronization therapy, with operator experience emerging as a critical factor. - The LECART trial demonstrated superior outcomes with LBBAP, primarily driven by reduced device-related complications requiring surgical reintervention, while the LEFT-BUNDLE-CRT trial failed to establish noninferiority. - Extended follow-up data from multiple studies suggest that while conduction-system pacing shows promise, biventricular pacing remains the established first-line therapy with the strongest evidence base. - Expert consensus indicates the field is moving toward individualized CRT approaches based on anatomy, conduction patterns, and operator expertise rather than universal replacement of conventional therapy.
- A phase 1 study evaluates TAR-210, an intravesical formulation of erdafitinib, for high- and intermediate-risk non-muscle invasive bladder cancer (NMIBC). - The study targets patients with FGFR alterations, present in 50-80% of advanced bladder cancer cases, aiming to improve outcomes. - Early data from cohorts 1 and 3 show potential efficacy in patients with recurrent high-grade or intermediate-risk NMIBC. - TAR-210 seeks to reduce systemic toxicities associated with systemic erdafitinib while maintaining therapeutic benefits.
- TAR-210, an intravesical delivery system for erdafitinib, demonstrates early clinical activity in patients with FGFR-altered high- and intermediate-risk NMIBC. - In high-risk NMIBC patients, TAR-210 achieved an estimated 12-month recurrence-free survival rate of 90% at a median follow-up of 8.9 months. - Among intermediate-risk NMIBC patients, TAR-210 showed a 90% complete response rate at 12 weeks, with 86% of complete responses ongoing at data cutoff. - A phase 3 study (MoonRISe-1) is underway to compare TAR-210 to standard of care in FGFR-altered intermediate-risk NMIBC.
- CAR-T cell therapy demonstrates remarkable efficacy in treating hematological malignancies, with CD19-targeted therapies achieving 67% complete remission rates in acute lymphoblastic leukemia and 82% objective response rates in non-Hodgkin lymphoma patients. - Serious adverse events occur in significant proportions of patients, with cytokine release syndrome affecting 11.67% of hematological cancer patients and neurological complications occurring in 20.20% of cases. - Management strategies including tocilizumab and corticosteroids have proven effective in controlling severe complications, with most adverse events being reversible when properly managed. - Academic centers play a crucial role in CAR-T development, sponsoring 35.4% of clinical trials globally, though Europe lags behind the US and China in trial numbers and industry collaboration.
